Department of Pathology, Uijeongbu Eulji Medical Center, School of Medicine, Eulji University, Uijeongbu-si 11759, Republic of Korea.
Department of Pathology, Chungnam National University Sejong Hospital, 20 Bodeum 7-ro, Sejong 30099, Republic of Korea.
Medicina (Kaunas). 2024 Sep 9;60(9):1475. doi: 10.3390/medicina60091475.
: This study aimed to elucidate the diagnostic role of α-Methylacyl-CoA racemase (AMACR) immunohistochemistry in gastric dysplasia and adenocarcinoma. : Immunohistochemistry for AMACR was performed on 39 gastric dysplasia and 40 gastric adenocarcinoma cases. The expression patterns of AMACR were investigated and divided into luminal and cytoplasmic expression patterns in the gastric lesions. In addition, correlations between AMACR expression and patient age, sex, and tumor size were evaluated. : AMACR was expressed in 26 of 39 cases of gastric dysplasia (66.7%) and 17 of 40 cases of gastric adenocarcinomas (42.5%). The AMACR expression rates in high- and low-grade dysplasia were 80.0% and 52.6%, respectively. A detailed analysis of the expression patterns revealed that the luminal expression pattern was significantly higher in low-grade dysplasia than in high-grade dysplasia and gastric adenocarcinoma ( < 0.001). The cytoplasmic expression pattern, without luminal expression, was predominant in high-grade dysplasia and gastric adenocarcinoma. In addition, the rates of loss of expression in the overall area were 15.1 ± 23.9%, 49.0 ± 29.9%, and 59.0 ± 32.2% in low-grade dysplasia, high-grade dysplasia, and gastric adenocarcinoma, respectively. The negative rate of low-grade dysplasia was significantly lower than that of high-grade dysplasia and gastric adenocarcinoma ( < 0.001 and < 0.001, respectively). : AMACR is a useful diagnostic marker for differentiating low-grade dysplasia from high-grade dysplasia and gastric adenocarcinoma. Luminal or cytoplasmic expression patterns and the extent of loss of expression are important for differentiation.
这项研究旨在阐明α-甲基酰基辅酶 A 消旋酶（AMACR）免疫组织化学在胃发育不良和腺癌中的诊断作用。
对 39 例胃发育不良和 40 例胃腺癌病例进行 AMACR 免疫组织化学染色。研究了 AMACR 的表达模式，并将胃病变中的表达模式分为腔和细胞质表达模式。此外，还评估了 AMACR 表达与患者年龄、性别和肿瘤大小之间的相关性。
AMACR 在 39 例胃发育不良中的 26 例（66.7%）和 40 例胃腺癌中的 17 例（42.5%）中表达。高级和低级发育不良中的 AMACR 表达率分别为 80.0%和 52.6%。对表达模式的详细分析表明，低级别发育不良的腔表达模式明显高于高级别发育不良和胃腺癌（<0.001）。无腔表达的细胞质表达模式在高级别发育不良和胃腺癌中占主导地位。此外，在整个区域丧失表达的比率分别为低级别发育不良 15.1±23.9%、高级别发育不良 49.0±29.9%和胃腺癌 59.0±32.2%。低级别发育不良的阴性率明显低于高级别发育不良和胃腺癌（<0.001 和 <0.001）。
AMACR 是区分低级别发育不良和高级别发育不良及胃腺癌的有用诊断标志物。腔或细胞质表达模式和丧失表达的程度对分化很重要。
